Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16369714 | 0.84 | CHRM4 (0.40) | HTR1AHTR7HTR6 | |
| SCHEMBL21631683 | 0.82 | PTPN11 (0.33) | PTPN11 | |
| SCHEMBL23229326 | 0.81 | PTPN11 (0.32) | PTPN11 | |
| SCHEMBL21653691 | 0.79 | PTPN11 (0.32) | PTPN11 | |
| SCHEMBL21653692 | 0.79 | PTPN11 (0.31) | PTPN11 | |
| SCHEMBL23208993 | 0.79 | HTR1A (0.35) | HTR1AHTR7HTR6 | |
| SCHEMBL20356533 | 0.77 | HTR1A (0.33) | HTR1AHTR7HTR6 | |
| SCHEMBL21653795 | 0.70 | LPL (0.32) | — | |
| SCHEMBL21631687 | 0.70 | CHRM4 (0.38) | — | |
| SCHEMBL23508727 | 0.69 | PTPN11 (0.34) | PTPN11CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112513050-B | Heterocyclic compounds which inhibit SHP2 activity | 大鹏药品工业株式会社 | 2024-12-20 | — | — | CN | disclosed |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220363693-A1 | HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| US-11466016-B2 | Pharmaceutical compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-10-11 | — | — | US | disclosed |
| WO-2021149817-A1 | Enhancement of anti-tumor activity of SHP2 inhibitor pyrimidinone in combination with novel cancer medicines in cancers | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021149817-A1 | Enhancement of anti-tumor activity of SHP2 inhibitor pyrimidinone in combination with novel cancer medicines in cancers | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-07-29 | — | — | WO | disclosed |
| EP-3827009-A1 | HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2 | Taiho Pharmaceutical Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-15 | — | — | US | disclosed |
| CN-112513050-A | Heterocyclic compounds inhibiting SHP2 activity | 大鹏药品工业株式会社 | 2021-03-16 | — | — | CN | disclosed |
| EP-3759111-A1 | PHARMACEUTICAL COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2021-01-06 | — | — | EP | disclosed |
| CN-111902415-A | Pharmaceutical compounds | 大冢制药株式会社 | 2020-11-06 | — | — | CN | disclosed |
| WO-2020022323-A1 | HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020022323-A1 | HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | MAPT, CYP3A5, SLC5A1 | HTR1A 3144/4885HTR7 1851/4885HTR6 2121/4885 |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | PTPN5, PTPN7, PTPN1 | HTR1A 4136/4885HTR7 3422/4885HTR6 4632/4885 |
| US-11466016-B2 | Pharmaceutical compounds | MAPT, CYP3A5, SLC5A1 | HTR1A 3144/4885HTR7 1851/4885HTR6 2121/4885 |
| US-20220363693-A1 | HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN9, PTPN7 | HTR1A 2999/4885HTR7 3382/4885HTR6 3552/4885 |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | PTPN1, PTPN9, PTPN7 | HTR1A 3265/4885HTR7 3702/4885HTR6 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.